HOOKIPA Pharma Inc.: directors' dealings · United States · SEC (Form 4)

About HOOKIPA Pharma Inc.

HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company listed on the U.S. NASDAQ market in the United States under the ticker HOOK. For French-, Belgian- and Swiss-based investors, this is best understood as a high-risk, high-optional biotech story: the investment case is driven by pipeline execution, clinical data, strategic transactions and funding capacity rather than by established commercial sales. The company originated in Europe as Hookipa Biotech and changed its name to HOOKIPA Pharma Inc. in June 2018. It completed its IPO in April 2019. HOOKIPA’s footprint is transatlantic, with corporate and investor-relations functions centered between New York and Vienna. That setup reflects both its scientific roots in Austria and its access to U.S. capital markets, which has been central to its financing and strategic flexibility. HOOKIPA’s core business is the development of a proprietary arenavirus-based immunotherapy platform designed to reprogram the immune system. Historically, the company has focused on two major therapeutic areas: infectious diseases and oncology. Its development work has included programs in hepatitis B and HIV, as well as next-generation therapeutic cancer vaccines. In competitive terms, HOOKIPA operates in a niche but crowded biotech universe alongside other immunotherapy, therapeutic-vaccine and viral-vector platform developers. In that arena, competitive advantage depends on the strength of clinical data, intellectual-property protection, manufacturing know-how and the ability to fund long development cycles. From a product and revenue perspective, HOOKIPA remains primarily a research and development company rather than a commercial-stage pharmaceutical group. That is important for financial analysis: near-term revenues are typically limited and uncertainty is high until a program reaches regulatory approval or a partnership delivers material proceeds. Its geographic presence is mainly in the United States and Austria, with U.S. market visibility through NASDAQ and SEC reporting. Recent corporate developments have been especially important. In 2025, HOOKIPA announced the sale of assets related to its HBV and HIV programs to Gilead Sciences. In 2026, it completed the sale of its oncology assets to NeoTrail Therapeutics. In July 2025, the company also announced its intention to voluntarily delist from NASDAQ and deregister its common stock. Taken together, these actions indicate a major strategic reset: monetizing legacy assets, simplifying the corporate structure and potentially changing the company’s future operating profile, rather than pursuing a conventional long-term platform-growth path.